Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 16/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4243437 | 0.93 | CHRNA7 (0.65) | CHRNA7KCNH2NPC1RAB9AHTT | |
| SCHEMBL13878556 | 0.92 | CHRNA7 (0.67) | CHRNA7KCNH2NPC1RAB9AHTT | |
| SCHEMBL13878559 | 0.90 | CHRNA7 (0.65) | CHRNA7KCNH2NPC1RAB9AALDH1A1 | |
| SCHEMBL13878563 | 0.88 | CHRNA7 (0.65) | CHRNA7KCNH2 | |
| SCHEMBL4246557 | 0.85 | CHRNA7 (0.76) | CHRNA7KCNH2HTTALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4238449 | 0.85 | CHRNA7 (0.63) | CHRNA7KCNH2NPC1RAB9AHTT | |
| Trifluoroacetic Acid SCHEMBL4244896 | 0.84 | CHRNA7 (0.61) | CHRNA7KCNH2NPC1RAB9AALDH1A1 | |
| SCHEMBL13878568 | 0.84 | CHRNA7 (0.65) | CHRNA7KCNH2RAB9A | |
| SCHEMBL13878574 | 0.84 | CHRNA7 (0.68) | CHRNA7KCNH2RAB9AALDH1A1 | |
| SCHEMBL13878545 | 0.84 | CHRNA7 (0.74) | CHRNA7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885KCNH2 815/4885NPC1 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.